Rice downgraded CVS Health's target price to $58.
Mizuho Securities Maintains CVS Health(CVS.US) With Buy Rating, Announces Target Price $58
Mizuho Adjusts Price Target on CVS Health to $58 From $66, Keeps Outperform Rating
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $80
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Prothena (PRTA) and CVS Health (CVS)
CVS Health: Strategic Buy Rating Amidst Industry Reforms and Valuation Opportunities
Baird Adjusts CVS Health Price Target to $51 From $61, Maintains Neutral Rating
Wells Fargo Trim Price Target on CVS Health to $65 From $66
Leerink Partners Maintains CVS Health(CVS.US) With Hold Rating, Cuts Target Price to $51
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $75
Evercore ISI Remains a Buy on CVS Health (CVS)
UBS Maintains CVS Health(CVS.US) With Hold Rating, Maintains Target Price $62
Morgan Stanley Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $63
Morgan Stanley Sticks to Its Buy Rating for CVS Health (CVS)
Bank of America: Dollar General (DG.US) inventory levels improve, upgrading the rating to "buy".
CVS Health Analyst Ratings
Deutsche Bank Upgrades CVS Health(CVS.US) to Buy Rating, Raises Target Price to $66
Piper Sandler has lowered the target price for CVS Health to $64.
Goldman Sachs raises the target price for CVS Health to $80.
CVS Health Is Maintained at Overweight by Piper Sandler
No Data